Jazz Pharmaceuticals plc Pays A Whopping $1 Billion For Rare Disease Drug Developer Gentium S.p.A.

In , the European Commission granted marketing authorization for Defitelio , the company's lead product, for the treatment of severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation.

http://www.biospace.com/news_story.aspx?StoryID=319212&full=1